Cited by 90Pharmacology and Obesity TreatmentAdipokines, Inflammation, and Metabolic DiseasesBerberine and alkaloids research

Obesity: pathophysiology and therapeutic interventions

Open access
Kong, Yue, Yang, Haokun, Nie, Rong, Zhang, Xuxiang, Zuo, Fan, Zhang, Hongtao, Nian, Xin·2025·Molecular Biomedicine

Abstract

Over the past few decades, obesity has transitioned from a localized health concern to a pressing global public health crisis affecting over 650 million adults globally, as documented by WHO epidemiological surveys. As a chronic metabolic disorder characterized by pathological adipose tissue expansion, chronic inflammation, and neuroendocrine dysregulation that disrupts systemic homeostasis and impairs physiological functions, obesity is rarely an isolated condition; rather, it is frequently complicated by severe comorbidities that collectively elevate mortality risks. Despite advances in nutritional science and public health initiatives, sustained weight management success rates and prevention in obesity remain limited, underscoring its recognition as a multifactorial disease influenced by genetic, environmental, and behavioral determinants. Notably, the escalating prevalence of obesity and its earlier onset in younger populations have intensified the urgency to develop novel therapeutic agents that simultaneously ensure efficacy and safety. This review aims to elucidate the pathophysiological mechanisms underlying obesity, analyze its major complications—including type 2 diabetes mellitus (T2DM), cardiovascular diseases (CVD), non-alcoholic fatty liver disease (NAFLD), obesity-related respiratory disorders, obesity-related nephropathy (ORN), musculoskeletal impairments, malignancies, and psychological comorbidities—and critically evaluate current anti-obesity strategies. Particular emphasis is placed on emerging pharmacological interventions, exemplified by plant-derived natural compounds such as berberine (BBR), with a focus on their molecular mechanisms, clinical efficacy, and therapeutic advantages. By integrating mechanistic insights with clinical evidence, this review seeks to provide innovative perspectives for developing safe, accessible, and effective obesity treatments.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s43556-025-00264-9

Cites

499 of 499 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Kong, Y., Yang, H., Nie, R., Zhang, X., Zuo, F., Zhang, H., & Nian, X.
Affiliations
  • First Affiliated Hospital of Kunming Medical University (CN)
  • Kunming Medical University (CN)
Corresponding author
  • Zhang, Hongtao
  • Nian, Xin
Venue
Molecular Biomedicine
Published
2025-04-25
Volume
6
Issue
1
Pages
25-25
ISSN
2662-8651 (ISSN-L)
OpenAlex
W4409818142
Cited by
89
References
499
Citations by year
2026: 77 · 2025: 12
FWCI
12.08
Type
journal article
Language
en
Open access
Locations
  • Molecular Biomedicine (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Kunming Medical University (RLMY20220005, CXTD202209, 202201AY070001-066)
  • Yunnan Provincial Science and Technology Department (202201AY070001)
Topics
  • Health Sciences › Medicine › Pharmacology › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Epidemiology › Adipokines, Inflammation, and Metabolic Diseases
  • Health Sciences › Medicine › Pharmacology › Berberine and alkaloids research
Keywords
obesity, obesity pathophysiology, adipose tissue expansion, chronic inflammation, neuroendocrine dysfunction, obesity-related comorbidities, type 2 diabetes, cardiovascular disease, non-alcoholic fatty liver disease, musculoskeletal impairment, psychological comorbidity, obesity pharmacotherapy, berberine, phytochemicals, weight management
MeSH terms
Animals, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Humans, Obesity, Anti-Obesity Agents, Non-alcoholic Fatty Liver Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review